(NASDAQ: UPB) Upstream Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.49%.
Upstream Bio's earnings in 2026 is -$122,774,000.On average, 8 Wall Street analysts forecast UPB's earnings for 2026 to be -$165,703,935, with the lowest UPB earnings forecast at -$204,417,182, and the highest UPB earnings forecast at -$146,390,543. On average, 6 Wall Street analysts forecast UPB's earnings for 2027 to be -$174,517,630, with the lowest UPB earnings forecast at -$210,772,120, and the highest UPB earnings forecast at -$134,475,034.
In 2028, UPB is forecast to generate -$283,632,353 in earnings, with the lowest earnings forecast at -$462,851,340 and the highest earnings forecast at -$141,283,896.